Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Amphion Innovations unveils new loan financing

Amphion Innovations unveils new loan financing

Amphion Innovations (LON:AMP) has secured a new loan facility to support its IP licensing programme and further develop its partner companies. 

Amphion is growing value by commercialising the intellectual property (IP) from seven partner firms, which are medical and technology focused. 

The financing is in the form of a new US$2mln share-backed loan from an institutional lender and there is potential to increase that to US$10mln, it said. 

Chief executive Richard Morgan told investors: "Amphion has expectations of cash inflows from several different sources over the next six to 12 months and this facility provides the capital we need to bridge to those inflows without incurring excessive dilution. 

"These funds will enable us to continue to support our IP licensing programme and the further development of our partner companies.” 

The loan is secured against Amphion’s holdings in Kromek and may be repaid at the company’s discretion in cash, the issue of Amphion shares, or the payment of Kromek shares where the lender will be subject to certain limitations. 

Amphion must repay the debt monthly starting on 1 September this year with the final payment due on June 1, 2015. 

The interest rate is 12% a year. As part of the deal, the lender will receive around 8.53 mln three-year warrants in Amphion with an exercise price of 4.375 pence per share. The current share price is 2.625p. 

In addition, Amphion will be issuing 663,627 simulated Kromek warrants at an exercise price of 56.25p. 

Richard Morgan added: “As a large shareholder of Kromek, Amphion remains committed to supporting the company and excited about its prospects.  Kromek has a strong technology platform that has the potential to make a major impact on medical imaging and other sectors.  We believe the very bright future of the company should be reflected in a much higher valuation in due course.  

"Amphion currently has some exciting developments underway, but in order to support our partner companies and progress our IP licensing programme we need access to additional capital.  This new financing will help Amphion to bring those developments to fruition.  I look forward to being able to report progress in the coming months and we believe that should allow us to retain our entire holding in Kromek." 

In April, the company announced it had received a favourable ruling in the US appeals court in cases involving computer giants SAP and Microsoft, which paves the way for its DataTern business to advance.


View full AMP profile View Profile

Amphion Innovations Plc Timeline

Related Articles

VW-plant.jpg
October 10 2017
Mike McAuliffe reckons the company's technology is 'tremendous', it is just a case of making the most of it commercially
Runner
January 17 2017
The shares ended 2016 at 8.89p having started it at 3.66p. Backers have consistently exercised warrants to acquire more shares.
XTEK: Access latest PPT from Proactive's CEO Sessions
June 18 2017
Philippe Odouard talked growing revenues with investors.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use